The PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist led IT intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices

ISRCTN ISRCTN21785299
DOI https://doi.org/10.1186/ISRCTN21785299
Secondary identifying numbers PS 024
Submission date
09/11/2006
Registration date
04/01/2007
Last edited
11/01/2018
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Study website

Contact information

Prof Anthony Avery
Scientific

Division of Primary Care
School of Community Health Sciences
University of Nottingham Medical School
Nottingham
NG7 2UH
United Kingdom

Phone +44 (0)115 823 0209
Email tony.avery@nottingham.ac.uk

Study information

Study designCluster randomised controlled trial.
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)GP practice
Study typePrevention
Scientific titleThe PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist led IT intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices
Study acronymPINCER Trial
Study hypothesisPrincipal research questions:
1. Is a pharmacist-led Information Technology (IT)-based intervention using educational outreach and practical support more effective than simple feedback in reducing rates of clinically important errors in medicines management in general practice?
2. What are the costs and benefits of the pharmacist-led intervention compared with simple feedback?
3. What are the views and experiences of health care professionals and NHS managers concerning the intervention, and what are the possible reasons why the interventions might be more effective in some practices than others?

Study hypotheses:
1. Pharmacist-led interventions will result in more than a 50% reduction in error rates for our primary outcome measures.
2. Simple feedback will result in no more than an 11% reduction in error rates (this is the 75% centile for change as a result of simple feedback in a Cochrane systematic review).
3. Benefits in error reduction in the pharmacist treatment arm will be sustained at 12 months.
Ethics approval(s)The study was given a favourable ethical opinion by Nottingham Research Ethics Committee 2 at the meeting held on 28 February 2005 (REC reference number: 05/Q2404/26).
ConditionInstances of potentially hazardous prescribing in general practice
InterventionPractices will be stratified by centre (Manchester or Nottingham) and size of practice. They will then be randomly allocated within strata to either the pharmacist intervention arm of the study or simple feedback.
All practices, irrespective of study arm, will be provided with computer-generated feedback (using Quest Browser software) on specific patients who are exposed to potentially hazardous prescribing and therefore at risk of morbidity.

In the "simple feedback" arm of the trial, practices will receive the computerised feedback along with brief written educational materials explaining the potential importance of the "problems" detected. They will be asked to try to make any changes to patients' medications within 12 weeks.

In the "pharmacist intervention" arm of the trial, an NHS-employed pharmacist will work part-time with each practice over a 12 week period. The pharmacist will arrange an initial meeting with members of the practice team to discuss the computer-generated feedback. They will take an "educational outreach" approach to explain the importance of the "problems" detected. Where appropriate they will employ the principles of root cause analysis to identify the underlying reasons for hazardous prescribing. The pharmacist will then work with the practice team to agree on the best way forward for addressing the problems identified and preventing their recurrence. The pharmacist will keep an anonymised record of the actions taken to correct hazardous prescribing or reasons given for not taking actions.
Intervention typeOther
Primary outcome measureThe proportion of patients in each practice:
1. Aged 18 years and older with a computer-recorded history of peptic ulcer being prescribed non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the previous six months without receiving drugs to protect against further peptic ulcer
2. Aged 18 years and older with a computer-recorded diagnosis of asthma being prescribed beta-blockers in the previous six months
3, Aged 75 years and older receiving long-term prescriptions for Angiotensin Converting Enzyme (ACE) inhibitors or loop diuretics without a recorded assessment of renal function and electrolytes in the previous 15 months

The proportions of "at risk" patients in each treatment arm with the errors of interest will be compared between treatment arms at six and 12 months after the end of the intervention period in each practice (the primary analysis will be undertaken using the six-month follow-up data).
Secondary outcome measuresSecondary outcome measures relate to a range of potential problems in the prescribing and monitoring of the following drugs:
1. Combined hormonal contraceptives
2. Warfarin
3. Lithium
4. Methotrexate
5. Amiodarone

The proportions of "at risk" patients in each treatment arm with the errors of interest will be compared between treatment arms at six and 12 months after the end of the intervention period in each practice (the primary analysis will be undertaken using the six-month follow-up data).
Overall study start date01/04/2006
Overall study end date31/03/2009

Eligibility

Participant type(s)Patient
Age groupOther
SexBoth
Target number of participants68 general practices
Participant inclusion criteria1. NHS general practices within a 50 mile radius of Manchester and Nottingham in England
2. Practices within Primary Care Trusts (PCTs) that agree to be involved in the study
3. Practices that have been laboratory-linked (or have other reliable systems for recording blood test results on the practice computer system) for at least 15 months prior to the time of baseline data collection
4. Practices that agree to participate in the study
Participant exclusion criteria1. Practices that state they do not routinely record morbidity such as asthma or peptic ulcer on the computer
2. Practices that do not use their computers to record prescriptions
3. Practices intending to change their General Practice (GP) computer systems to that of a different supplier which is not Quest Browser compatible during the course of the study
4. Practices in PCTs that are undertaking interventions that might overlap with our intervention
5. Practices that were involved in our pilot study
6. Practices that do not agree to the installation of Quest Browser software on their practice computers (this software is essential for generating patient-specific data on patients with medication errors)
7. Practices that expect major changes in list size during the course of the study, either because of the splitting up of the practice, merger with other practices or any other reason for a large influx or loss of patients
Recruitment start date01/04/2006
Recruitment end date31/03/2009

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Division of Primary Care
Nottingham
NG7 2UH
United Kingdom

Sponsor information

Patient Safety Research Programme of the Department of Health (UK)
Government

c/o Mrs Jo Foster
Patient Safety Research Portfolio
Department of Public Health and Epidemiology
The University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom

Website http://www.pcpoh.bham.ac.uk/publichealth/psrp/
ROR logo "ROR" https://ror.org/03n0qh685

Funders

Funder type

Government

Department of Health (Leeds), part of Patient Safety Research Programme (funding reference number: PS/024).

No information available

Nottingham Primary Care Research Partnership NHS R&D Support Funding (funding reference number: 2006/07).

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 01/05/2009 Yes No
Results article results 07/04/2012 Yes No

Editorial Notes

11/01/2018: publication reference added.